Dynavax Technologies

Dynavax Technologies is a California-based company in the biotechnology industry with a focus on developing novel vaccines. Its first commercial product was a Hepatitis B vaccine called HEPLISAV-B.It develops its medical solutions using Toll-like Receptor (TLR) technology.

COVID-19

The company entered into a partnership with Clover Biopharmaceuticals, a Chinese biotechnology company, to develop a vaccine candidate for COVID-19. The company's roll in the partnership includes technical expertise as well as CpG 1018, an adjuvant that is used in creating vaccines such as the company's own HEPLISAV-B.

Dynavax Technologies also partnered with Sinovac to combine its adjuvant CpG 1018 with Sinovac's chemically inactivated vaccine candidate for COVID-19.

Timeline

May 27, 2021

Dynavax Technologies Corporation enters into a commercialization agreement with Bavarian Nordic.

Funding rounds

Products

Acquisitions

SBA Awards

Patents

Products

People

Name

Role

Albert Robinson

Employee

Anton Stetsenko

Employee

Astrid Liong

Employee

Augie Kuo

Investor

David Novack

President and COO

Documentaries, videos and podcasts

Title

Date

Link

The Next Big Thing In Biotech: Dynavax

November 9, 2012

https://www.youtube.com/watch?v=92BWpQG_MH4

Companies

Company

CEO

Location

Products/Services

News

Title

Author

Date

Publisher

Description

Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany

BioSpace

May 27, 2021

BioSpace

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Clover Biopharmaceuticals

February 1, 2021

www.prnewswire.com:443

/PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines...